Indeed, the authors reported that increasing the PERK/NRF2 signaling pathway was the origin of a developed cross-resistance to chemotherapy in human cell lines originating from breast cancer, colon cancer, and osteosarcoma. The gene discussed is EIF2AK3; the disease is osteosarcoma.